Trial Outcomes & Findings for High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients (NCT NCT02932332)
NCT ID: NCT02932332
Last Updated: 2023-04-21
Results Overview
We assessed dyspnea intensity 'now' using a numeric rating scale from 0 to 10 where 0=none and 10=worst. The minimal clinically important difference was 1 point.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
26 participants
Primary outcome timeframe
0 (baseline) minutes and at 10 minutes
Results posted on
2023-04-21
Participant Flow
Patients were recruited from MD Anderson Cancer Center with active cancer diagnosis , having age \>=18, an average dyspnea numeric rating scale of ≥4/10 over the past 24 hours, oxygen saturation \>90% on ambient air and able to tolerate high flow nasal canula.
19 patients were randomized for this study. 7 patients were not randomized for various reasons (discharged too early=3, changed mind=2 and others =2)
Participant milestones
| Measure |
Group 1 High Flow Air (HFAir-LFAir-HFOx-LFOx)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 2 High Flow Oxygen (HFOx-HFAir-LFOx-LFAir)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 3 Low Flow Air (LFAir-LFOx-HFAir-HFOx)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 4 Low Flow Oxygen (LFOx-HFOx-LFAir-HFAir)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
5
|
4
|
5
|
5
|
|
Overall Study
Intervention 1
|
4
|
4
|
5
|
4
|
|
Overall Study
Intervention 2
|
4
|
3
|
4
|
4
|
|
Overall Study
Intervention 3
|
3
|
2
|
4
|
3
|
|
Overall Study
Intervention 4
|
3
|
1
|
4
|
3
|
|
Overall Study
COMPLETED
|
3
|
1
|
4
|
3
|
|
Overall Study
NOT COMPLETED
|
2
|
3
|
1
|
2
|
Reasons for withdrawal
| Measure |
Group 1 High Flow Air (HFAir-LFAir-HFOx-LFOx)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 2 High Flow Oxygen (HFOx-HFAir-LFOx-LFAir)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 3 Low Flow Air (LFAir-LFOx-HFAir-HFOx)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 4 Low Flow Oxygen (LFOx-HFOx-LFAir-HFAir)
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
|---|---|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
0
|
1
|
|
Overall Study
Chest pain
|
0
|
0
|
0
|
1
|
|
Overall Study
Not Dyspneic cough
|
1
|
2
|
1
|
0
|
Baseline Characteristics
High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
Baseline characteristics by cohort
| Measure |
Group 1 High Flow Air (HFAir-LFAir-HFOx-LFOx)
n=5 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 2 High Flow Oxygen (HFOx-HFAir-LFOx-LFAir)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 3 Low Flow Air (LFAir-LFOx-HFAir-HFOx)
n=5 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Group 4 Low Flow Oxygen (LFOx-HFOx-LFAir-HFAir)
n=5 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min
|
Total
n=19 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
55 years
n=5 Participants
|
48 years
n=7 Participants
|
50 years
n=5 Participants
|
51 years
n=4 Participants
|
51 years
n=21 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
11 Participants
n=21 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
8 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
17 Participants
n=21 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
15 Participants
n=21 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
|
Region of Enrollment
United States
|
5 participants
n=5 Participants
|
4 participants
n=7 Participants
|
5 participants
n=5 Participants
|
5 participants
n=4 Participants
|
19 participants
n=21 Participants
|
|
Cancer Stage
II
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
|
Cancer Stage
III
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
|
Cancer Stage
IV
|
5 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
17 Participants
n=21 Participants
|
|
Cancer Type
Breast
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
|
Cancer Type
Gastrointestinal
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
7 Participants
n=21 Participants
|
|
Cancer Type
Genitourinary
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
|
Cancer Type
Gynecological
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
|
Cancer Type
Hematologic
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
|
Cancer Type
Thoracic
|
1 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
|
Cancer Type
Other
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
|
Dyspnea for reason of admission
Yes
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
9 Participants
n=21 Participants
|
|
Dyspnea for reason of admission
No
|
3 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
|
Supplement Oxygen
Yes
|
3 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
9 Participants
n=21 Participants
|
|
Supplement Oxygen
No
|
2 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
10 Participants
n=21 Participants
|
PRIMARY outcome
Timeframe: 0 (baseline) minutes and at 10 minutesPopulation: Participants who completed the first intervention.
We assessed dyspnea intensity 'now' using a numeric rating scale from 0 to 10 where 0=none and 10=worst. The minimal clinically important difference was 1 point.
Outcome measures
| Measure |
Group 1 High Flow Air (HFAir-LFAir-HFOx-LFOx)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 2 High Flow Oxygen (HFOx-HFAir-LFOx-LFAir)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 3 Low Flow Air (LFAir-LFOx-HFAir-HFOx)
n=5 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 4 Low Flow Oxygen (LFOx-HFOx-LFAir-HFAir)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
|---|---|---|---|---|
|
Change in Dyspnea Numeric Score Between 0 and 10 Minutes
|
-1.8 score on a scale
Interval -3.0 to -0.5
|
-1.8 score on a scale
Interval -2.8 to -0.7
|
-0.6 score on a scale
Interval -1.3 to 0.2
|
-0.5 score on a scale
Interval -1.0 to 0.1
|
SECONDARY outcome
Timeframe: 0 (baseline) minutes and at 10 minutesPopulation: Participants who completed the first intervention
We assessed dyspnea intensity 'now' using a Modified Dyspnea Borg scale. This is a 0-10 point ratio scale with a higher score indicating worse dyspnea.
Outcome measures
| Measure |
Group 1 High Flow Air (HFAir-LFAir-HFOx-LFOx)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 2 High Flow Oxygen (HFOx-HFAir-LFOx-LFAir)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 3 Low Flow Air (LFAir-LFOx-HFAir-HFOx)
n=5 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 4 Low Flow Oxygen (LFOx-HFOx-LFAir-HFAir)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
|---|---|---|---|---|
|
Change in Modified Borg Scale Intensity Between 0 and 10 Minutes
|
-0.7 score on a scale
Interval -1.6 to 0.2
|
-1.8 score on a scale
Interval -2.8 to -0.7
|
-0.1 score on a scale
Interval -0.4 to 0.2
|
-0.5 score on a scale
Interval -1.2 to 0.2
|
SECONDARY outcome
Timeframe: 0 (baseline) minutes and at 10 minutesPopulation: Participants who completed the first intervention.
We assessed dyspnea unpleasantness 'now' using a Modified Dyspnea Borg scale. This is a 0-10 point ratio scale with a higher score indicating worse dyspnea unpleasantness.
Outcome measures
| Measure |
Group 1 High Flow Air (HFAir-LFAir-HFOx-LFOx)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 2 High Flow Oxygen (HFOx-HFAir-LFOx-LFAir)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 3 Low Flow Air (LFAir-LFOx-HFAir-HFOx)
n=5 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
Group 4 Low Flow Oxygen (LFOx-HFOx-LFAir-HFAir)
n=4 Participants
High Flow Oxygen and High Flow Air was delivered between 20 and 60 L/min. Low Flow Oxygen and Low Flow Air was delivered at 2L/min.
|
|---|---|---|---|---|
|
Change in Modified Borg Scale Unpleasantness Between 0 and 10 Minutes
|
-0.5 score on a scale
Interval -1.6 to 0.5
|
-1.8 score on a scale
Interval -3.3 to -0.4
|
-0.6 score on a scale
Interval -1.5 to 0.2
|
-0.7 score on a scale
Interval -1.6 to 0.2
|
Adverse Events
High Flow Air
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
High Flow Oxygen
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Low Flow Air
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Low Flow Oxygen
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
High Flow Air
n=12 participants at risk
High Flow Air was delivered between 20 and 60 L/min.
|
High Flow Oxygen
n=13 participants at risk
High Flow Oxygen was delivered between 20 and 60 L/min.
|
Low Flow Air
n=13 participants at risk
Low Flow Air was delivered at 2L/min.
|
Low Flow Oxygen
n=13 participants at risk
Low Flow Oxygen was delivered at 2L/min.
|
|---|---|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Dry Nose
|
16.7%
2/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
30.8%
4/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
53.8%
7/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
|
Respiratory, thoracic and mediastinal disorders
Moisture in nose
|
58.3%
7/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
46.2%
6/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
38.5%
5/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal prong uncomfortable
|
41.7%
5/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
38.5%
5/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
23.1%
3/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
38.5%
5/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
|
Nervous system disorders
Anxiety
|
33.3%
4/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
23.1%
3/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
30.8%
4/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
7.7%
1/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
|
Respiratory, thoracic and mediastinal disorders
Feeling of suffocation
|
33.3%
4/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
0.00%
0/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
|
Respiratory, thoracic and mediastinal disorders
Trouble talking
|
25.0%
3/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
30.8%
4/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
|
Nervous system disorders
Dry eyes
|
8.3%
1/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
7.7%
1/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
7.7%
1/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
|
Nervous system disorders
Eye irritation
|
0.00%
0/12 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
15.4%
2/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
0.00%
0/13 • baseline and 10 minutes of each intervention.
Adverse effects such as dry eyes, dry nose, nasal moisture and anxiety were assessed using a 0-10 numeric rating scale, where 0=none and 10=worst possible. The participants 'at risk' are a total number of participants combined that received specific intervention from each group at different sequences.
|
Additional Information
David Hui, MD, Associate Professor/Palliative Care Med
UT MD Anderson Cancer Center
Phone: 713-792-6258
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place